NCT03581487 2025-11-05Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung CancerM.D. Anderson Cancer CenterPhase 1/2 Completed40 enrolled
NCT03693612 2024-08-28GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid TumorsGlaxoSmithKlinePhase 1/2 Completed26 enrolled 47 charts